- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00776139
Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions
An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fasting Condition
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study was conducted as an open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing containing 10 mg cetirizine hydrochloride study comparing to the marketed product, Zyrtec®, containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in healthy, adult, human, subjects under fasting condition.
Safety measures were performed throughout the study and included a physical examination, laboratory evaluation, and measurement of vital signs.
A total of 32 subjects were randomized to receive single oral dose of cetirizine hydrochloride 10 mg tablet and 31 subjects completed both the periods of the study.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Bioanalytical Systems, Inc.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Aged 18-50 years.
- Were within 18 to 29.9 kilograms/m2 per the BMI (Determination of Body Mass Index).
- Had voluntarily given written informed consent to participate in this study.
- Were of normal health as determined by medical history and physical examination of the subjects performed within 30 days prior to the commencement of the study.
- Blood chemistry, hematology, and urinalysis tests performed within 30 days prior to the start of the study must be within clinically acceptable limits upon evaluation by the Investigator.
- Subjects must have screening and check-in (each period) blood pressure and pulse rate within the protocol specified ranges.
- If female and of childbearing potential, the subject was counseled on the importance of not becoming pregnant before or during the study, and the subject had a negative pregnancy test at the pre-treatment visit.
Exclusion Criteria:
- History of clinically significant organ-system (cardiovascular, neurological, hepatic, hematopoietic, pulmonary, endocrine, or gastrointestinal) disorders, or ongoing infectious diseases.
- history of alcohol abuse or drug addiction requiring treatment within the last 12 months.
- Presence or history of renal impairment or chronic liver disease.
- History of jaundice (yellowing of the skin or whites of the eyes).
- Participation in an investigationaldrug study or donation of blood within 30 days prior to the start of the study.
- Known allergy or sensitivity to cetirizine (Zyrtec®), or to related drugs such as hydroxyzine (Vistaril® or Ataraxl®).
- Prescription drug use (excluding hormonal contraceptives) within 14 days prior to drug administration, each period. Subject is taking macrolide antibiotics, such as erythromycin, azithromicin, ketoconazole, or related drugs.
- Ingestion of grapefruit juice or grapefruit-containg products within 72 hours prio to drug administration, each period.
- Alcohol consumption 24 hours prior to drug administration, each period.
- Caffeine or xanthine consumption for at least 10 hours prior to drug administration, each period.
- Female subjects who are pregnant or nursing.
- Positive HIV 1, Hepatitis B surface antigen, and urine screen for drugs of abuse within 30 days prior to the start of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
|
Bioequivalence Cetirizine Hydrochloride 10 mg tablet
|
Experimental: 2
Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
|
Bioequivalence Cetirizine Hydrochloride 10 mg tablet
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Bioequivalencia
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 11821
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cetirizine Hydrochloride 10 mg tablet
-
Kremers Urban Development CompanyWatson Laboratories, Inc.Terminado
-
Kremers Urban Development CompanyTerminado
-
Kremers Urban Development CompanyTerminadoSaludableEstados Unidos
-
AstraZenecaTerminadoSíndrome de Zollinger-Ellison | Esofagitis por reflujo (RE) | Úlcera gástrica (GU) | Úlcera Duodenal (DU) | Úlcera anastomótica (AU) | Enfermedad de esofagitis por reflujo no erosiva (NERD)Japón
-
Dong-A ST Co., Ltd.TerminadoSaludableCorea, república de
-
The Netherlands Cancer InstituteTerminado
-
Merck Sharp & Dohme LLCTerminado
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityTerminado
-
Vedic Lifesciences Pvt. Ltd.Aún no reclutandoInfecciones del Tracto Respiratorio SuperiorIndia
-
Merck Sharp & Dohme LLCTerminado